DRKS00008766已完成1 期
An open randomized single dose cross-over study to investigate the relative bioavailability (BA) of different formulations containing crystalline glucosamine sulphate: Film-coated tablet (dona® 750 mg) and oral soluble powder formulation presented as a sachet (dona® 1500 mg) in healthy subjects under different fasted and fed conditions - X-03178-3307
MEDA Pharma GmbH & Co. KG (a Mylan company), Scientific Affairs, Head of Clinical Affairs Meda0 个研究点目标入组 39 人开始时间: 2015年6月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 39
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Healthy male and female of any ethnic origin.
- •2.Age range from 18 to 55 years inclusive.
- •3.Body mass index (BMI) from 18.5 to 30.0 kg/m2 inclusive.
- •4.Written informed consent.
排除标准
- •- History of allergic reaction or hypersensitivity to glucosamine or excipients of the study medication.
- •- The oral soluble powder formulation contains aspartame and is therefore contraindicated in patients with phenylketonuria.
- •- History of diabetes mellitus or impaired mono-/disaccharides tolerance.
- •- Positive ß-HCG pregnancy test, established pregnancy, or breast-feeding at screening or during the study, or planned pregnancy
- •- Clinically significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, endocrine, haematological, metabolic, neurological or psychiatric, or any other significant diseases, or significant finding, which may interfere with the pharmacokinetics of drugs.
- •- Clinically relevant significant laboratory findings that, in the opinion of the investigator, would preclude inclusion in the trial.
- •- Chronic or clinically relevant acute infections, febrile disease or any acute illness two weeks prior to Screening.
- •- Electrocardiogram (ECG) abnormalities of clinical relevance
- •- Abnormal vital signs (heart rate, blood pressure, and pulse rate).
- •- History of malignancy within the past five years.
- •- Continuous or regular use of any concomitant medication
- •- Consumption of food or food supplements interferring with pharmacokinetics
- •- Exposure to any CYP3A4 inhibiting or inducing diets or beverages.
- •- Presence or history of drug or alcohol abuse, or consumption of significant amounts of alcoholic bevarages or cigerattes/day.
- •- Blood donation within the last 2 months prior to study.
- •- Lack of ability or willingness to give informed consent or to co-operate adequately.
研究者
相似试验
已完成
不适用
Randomized, open, single dose, cross-over study to validate a composite endpoint for acceptability evaluation of oral drug formulations in the paediatric populatioAll paediatric patients who present to the Clinic for General Paediatrics, Neonatology and Paediatric Cardiology at the University Hospital Düsseldorf as outpatients or inpatients and who are able to swallow.DRKS00027948Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie, Universitätsklinik Düsseldorf320
已完成
不适用
A Randomized, Single-dose, Cross-over Study to Investigate the Suitability of Multiple Placebo Mini-tablet Administration in Small Childreo specific disease. Placebo Administration to hospitalised patients.DRKS00008843Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie, Universitätsklinik Düsseldorf374
已完成
不适用
A Randomized, Single-dose, Cross-over Study to Investigate the Acceptability of an Orodispersible Film Compared to Syrup in Neonates and Infantso specific disease. Placebo Administration to hospitalised patients.DRKS00011325Klinik für Allgemeine Pädiatrie, Neonatologie und Kinderkardiologie, Universitätsklinik Düsseldorf150
已完成
1 期
Relative bioavailability of fingolimod (2Ã?0.25 mg) vs. FMI, 0.5 mg capsule in healthy volunteersCTRI/2012/01/002326ovartis Healthcare Private Limited42
已完成
不适用
A study to assess the processing of nicotine by the body and subjective effects of oral nicotine products in healthy adult users of cigarettes and smokeless pouch productsicotine uptake and subjective measuresISRCTN10633589British American Tobacco (United Kingdom)40